TL;DR:
- Tampa General Hospital Cancer Institute employs AI-driven CyberKnife S7 for precision radiosurgery.
- CyberKnife S7 offers non-invasive radiation therapy with real-time motion tracking.
- The system can treat a wide range of tumors and neurologic disorders in short sessions.
- Dr. Richard Tuli leads the initiative, bringing extensive experience from Memorial Sloan Kettering.
- Accuray Incorporated develops the innovative CyberKnife S7 technology.
- Real-time tracking and AI enhance precision in stereotactic radiosurgery.
- Expanded radiation delivery angles protect healthy tissue while targeting tumors.
- Plans for a Proton Therapy Center signify further advancements in cancer care.
- Tampa General Hospital’s commitment to innovation and patient-centric services is evident in its expansion.
Main AI News:
In the realm of medical innovation, Tampa General Hospital (TGH) Cancer Institute stands at the forefront, transforming the landscape of cancer treatment through cutting-edge technology. The institute has embraced the power of artificial intelligence (AI) with open arms, leveraging it to usher in a new era of hope and precision in the fight against cancer.
The CyberKnife S7, a state-of-the-art robotic radiation therapy device, takes center stage in this medical revolution. This non-invasive wonder harnesses real-time AI-driven motion tracking and synchronization, enabling it to deliver precision treatments like stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). Its capabilities extend beyond the imagination, with the ability to target cancerous and benign tumors throughout the body, along with addressing neurologic disorders, all accomplished in as little as 15 minutes.
Dr. Richard Tuli, a distinguished expert and leader in the field, serves as the driving force behind this remarkable transformation. As the professor and chair of the Department of Radiation Oncology at USF Health Morsani College of Medicine, deputy director of the TGH Cancer Institute, and director of Radiation Oncology at Tampa General, Dr. Tuli brings a wealth of experience from his tenure at Memorial Sloan Kettering Cancer Center in New York, N.Y.
“It’s another example of providing our patients with the best possible care across the Tampa Bay region and the state,” he said. “Using true robotic precision for personalized therapy, this new Cyberknife S7 is at the forefront of treating tumors, and greatly enhances what the TGH Cancer Institute can offer as an alternative to treating difficult tumors that are otherwise difficult to reach with more conventional cancer treatments.”
Accuray Incorporated, the visionary company behind the CyberKnife S7, has developed a game-changer in the medical world. This remarkable tool is designed to target cancerous and non-cancerous tumors across a spectrum of locations within the body, including the prostate, lung, brain, spine, head, neck, liver, kidney, and pancreas. It presents a viable alternative to surgery, especially for patients facing inoperable or surgically complex tumors, with treatments typically completed in one to five sessions.
During cancer treatment, a multitude of variables come into play – patient movement, breathing patterns, muscle contractions, and the displacement of fluids and gases within the body. These factors can impact the precise targeting of the tumor by the radiation beam. However, the CyberKnife S7 rises to the challenge by tracking these changes and adapting in real-time, making the procedure significantly more effective and less risky.
Dr. Brian Collins, a board-certified radiation oncologist and professor of Radiation Oncology, applauds the CyberKnife S7 as a remarkable oncology tool. “Ten years ago, no one would have thought this kind of technology was possible,” he said. Stereotactic radiosurgery, a highly precise form of therapeutic radiation, has reached unprecedented accuracy with the incorporation of real-time tracking and AI, exemplified by the CyberKnife S7.
This robotic system introduces a revolution in radiation delivery, offering thousands of unique angles for delivering radiation beams to the patient. This expanded range of options allows physicians to precisely target the tumor while safeguarding the surrounding healthy tissue, maximizing the effectiveness of the treatment.
“The establishment of the Center for Precision Radiosurgery at TGH Cancer Institute and the ability to provide precision treatment with the Cyberknife S7 highlight our unwavering commitment to a highly personalized, innovative, and compassionate cancer care that meets the unique needs of each patient,” emphasizes Dr. Eduardo Sotomayor, vice president, and executive director of TGH Cancer Institute.
The Radiation Oncology platform at TGH Cancer Institute boasts a comprehensive range of services for treating all types of cancers. It offers evidence-based, multidisciplinary care incorporating cutting-edge radiation therapies, including the TrueBeam™ system, high-dose-rate (HDR) brachytherapy, and radiopharmaceuticals. Additionally, plans for a 44,000-square-foot Proton Therapy Center adjacent to downtown Tampa promise to further elevate the standard of care.
In 2023, the TGH Cancer Institute expanded its reach with a satellite location at the TGH Outpatient Center in Brandon. This facility boasts advanced equipment and services, including a 26-bay Infusion Center, a Radiation Oncology Center, and a team of experts specializing in various cancer types. Dr. Abraham Schwarzberg, executive vice president, chief of Oncology, and president of the Tampa General Provider Network (TGPN), affirms the institution’s commitment to innovation and patient-centric services.
“As one of the nation’s leading academic medical centers, we are focused on driving innovation to give patients the finest treatment options possible, and this is a perfect example,” he said. “Our Radiation Oncology enhancements, including CyberKnife, show how we are bringing the most advanced resources directly to those who need them the most.”
Conclusion:
Tampa General Hospital’s adoption of the CyberKnife S7 and its commitment to innovative cancer care signify a major advancement in the market. The integration of AI-driven precision radiosurgery technology not only enhances patient outcomes but also establishes the hospital as a leader in academic medicine, setting a new standard for cancer treatment centers.
